For Mounjaro, the doses range from 2.5 mg to 15 mg, with gradual dose increases over time
Still, the analysts predicted that Ozempic, Wegovy, and Rybelsus (semaglutide) maker Novo Nordisk and Eli Lilly, which developed Zepbound and Mounjaro (tirzepatide), will maintain two-thirds of the market by 2031 due to their first-mover advantages. Other competitors are expected to take a combined $70 billion of the GLP-1 market, the study read
Palatin Technologies has developed a variation of MT-II called bremelanotide (PT-141), which exhibits MT-IIs specific benefits related to sexual stimulation [4]
Nem szabad abban a hitben ringatni magunkat, hogy a gygyszer majd szpen leviszi a slyt, s nem kell semmit tennnk ehhez
(Chiang CH, senior author)